Skip to main content
. 2022 Apr 5;29(10):1982–1995. doi: 10.1038/s41418-022-00990-5

Fig. 8. Fer-1 administration abrogated the detrimental effect on DIC mediated by PRMT4.

Fig. 8

AAV-NC or AAV-PRMT4 were applied via tail vein injection, 2 weeks later, Fer-1 was injected intraperitoneally 2 h before establishment of the DIC model. a Representative images of M-mode echocardiograms; b Representative Masson staining images, Scale bar, 50 μm; c Representative DHE staining images were shown, Scale bar, 20 μm; d–f Quantitative analysis of LVEF (d, *P < 0.001, #P < 0.01, $P < 0.01), FS (e, *P < 0.001, #P < 0.01, $P < 0.01), and LVEDV (f, *P < 0.05, #P < 0.05, $P < 0.05) by echocardiography; g–i; Quantitative analysis of serum CK-MB (g, *P < 0.001, #P < 0.05, $P < 0.05), AST (h, *P < 0.01, #P < 0.001, $P < 0.001), and LDH (i, *P < 0.001, #P < 0.01, $P < 0.001); j Relative ROS intensity was statistically analyzed, *P < 0.001, #P < 0.001, $P < 0.001; k–m Quantitative analysis of GSH level (k, *P < 0.001, #P < 0.01, $P < 0.01), MDA level (l, *P < 0.001, #P < 0.05, $P < 0.05), and GPX4 activity (m, *P < 0.001, #P < 0.001, $P < 0.001); n Quantitative analysis of fibrosis area, *P < 0.001, #P < 0.001, $P < 0.01; o Quantitative analysis of TUNEL positive cells by immunofluorescence staining, *P < 0.001, #P < 0.001, $P < 0.001.